振东制药
(300158)
| 流通市值：51.87亿 | | | 总市值：51.90亿 |
| 流通股本：9.92亿 | | | 总股本：9.92亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,096,512,580.03 | 649,133,317.06 | 2,783,059,374.58 | 2,214,507,098.61 |
| 营业总成本 | 1,174,522,984.88 | 657,931,700.5 | 3,109,138,419 | 2,206,677,387.24 |
| 其他经营收益 | | | | |
| 营业利润 | -93,909,957.06 | 3,948,416.1 | -264,937,794.18 | 54,010,760.32 |
| 利润总额 | -97,140,430.14 | 2,949,411.01 | -277,622,698.41 | 45,741,309.38 |
| 净利润 | -95,301,962.62 | -1,188,686.9 | -303,086,623.19 | 18,375,743 |
| 每股收益 | | | | |
| 其他综合收益 | 130,132.49 | -2,794.77 | 1,101,205.69 | -736,346.78 |
| 综合收益总额 | -95,171,830.13 | -1,191,481.67 | -301,985,417.5 | 17,639,396.22 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,253,728,104.77 | 2,497,861,585.53 | 2,668,188,159.18 | 2,642,541,930.49 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,019,863,051.33 | 1,975,366,631.88 | 1,953,937,810.71 | 1,868,790,188.46 |
| 资产总计 | 4,273,591,156.1 | 4,473,228,217.41 | 4,622,125,969.89 | 4,511,332,118.95 |
| 流动负债: | | | | |
| 流动负债合计 | 970,955,018.15 | 1,077,274,212.53 | 1,270,012,157.84 | 842,021,361.23 |
| 非流动负债: | | | | |
| 非流动负债合计 | 85,915,331.41 | 87,535,622.47 | 42,559,537.52 | 40,632,945.86 |
| 负债合计 | 1,056,870,349.56 | 1,164,809,835 | 1,312,571,695.36 | 882,654,307.09 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,256,647,486.32 | 3,347,959,103 | 3,348,952,218.78 | 3,668,039,158.66 |
| 股东权益合计 | 3,216,720,806.54 | 3,308,418,382.41 | 3,309,554,274.53 | 3,628,677,811.86 |
| 负债和股东权益合计 | 4,273,591,156.1 | 4,473,228,217.41 | 4,622,125,969.89 | 4,511,332,118.95 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,039,813,326.95 | 477,365,462.09 | 2,631,618,666.93 | 1,872,105,510.29 |
| 经营活动现金流出小计 | 1,387,704,906.2 | 781,427,338.52 | 3,092,098,393.74 | 2,474,842,360.86 |
| 经营活动产生的现金流量净额 | -347,891,579.25 | -304,061,876.43 | -460,479,726.81 | -602,736,850.57 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,314,857,577.7 | 599,862,868.17 | 3,025,846,727.99 | 2,638,375,587.97 |
| 投资活动现金流出小计 | 1,344,744,130.97 | 692,561,814.41 | 2,729,146,207.07 | 2,246,942,734.69 |
| 投资活动产生的现金流量净额 | -29,886,553.27 | -92,698,946.24 | 296,700,520.92 | 391,432,853.28 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 155,378,187.02 | 151,894,052.04 | 198,613,566.15 | 33,210,307.3 |
| 筹资活动现金流出小计 | 7,103,886.23 | 2,744,027.99 | 100,981,763.54 | 96,617,740.66 |
| 筹资活动产生的现金流量净额 | 148,274,300.79 | 149,150,024.05 | 97,631,802.61 | -63,407,433.36 |
| 汇率变动对现金及现金等价物的影响 | - | - | - | - |
| 现金及现金等价物净增加额 | -229,503,831.73 | -247,610,798.62 | -66,147,403.28 | -274,711,430.65 |
| 期末现金及现金等价物余额 | 262,364,037.48 | 244,257,070.59 | 491,867,869.21 | 283,303,841.84 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -229,503,831.73 | - | -66,147,403.28 | - |